Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

19.95 +0.43 (+2.23%)
Streaming Delayed Price Updated: 11:16 AM EST, Dec 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about uniQure N.V. - Ordinary Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday? ↗
uniQure's AMT-130 receives FDA Breakthrough Therapy designation for Huntington's disease, adding to Fast Track, RMAT, and Orphan Drug statuses. 
Via Benzinga
News headline image
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years ↗
CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and eliminating prophylaxis need for most patients at year four. 
Via Benzinga
News headline image
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Pricing of its Public Offering
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Proposed Public Offering
From uniQure Inc.
Via GlobeNewswire
News headline image
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025? ↗
Via The Motley Fool
News headline image
S&P 500 Edges Lower; AutoZone Posts Downbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earnings ↗
 
Via Benzinga
News headline image
United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Dow Falls 150 Points; Oracle Posts Downbeat Results ↗
 
Via Benzinga
Topics Stocks
News headline image
UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug ↗
The company is testing a gene therapy for Huntington's disease and could soon seek an accelerated approval. 
Via Investor's Business Daily
News headline image
Why Is uniQure Stock Skyrocketing On Tuesday? ↗
uniQure stock surges after FDA agrees on an accelerated approval pathway for its Huntington's disease treatment, AMT-130. 
Via Benzinga
News headline image
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
From uniQure Inc.
Via GlobeNewswire
CS Diagnostics (OTC: FZRO) Acquisitions Announced, Landmark Agreement Signed, Moving Forward Through 2024
Via AB Newswire
Topics Intellectual Property
News headline image
QURE Stock Earnings: uniQure Beats EPS, Beats Revenue for Q2 2024 ↗
QURE stock results show that uniQure beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
From uniQure Inc.
Via GlobeNewswire
News headline image
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Why Are UniQure Shares Surging Today? ↗
UniQure N.V. (NASDAQ: QURE) shares are skyrocketing Wednesday following the release of promising interim data from its Phase I/II clinical trials of AMT-130, a gene therapy targeting Huntington's... 
Via Benzinga
News headline image
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
SMART Global Posts Upbeat Results, Joins Aehr Test Systems, MarineMax And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.